Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
27 juin 2019 08h30 HE
|
Zenith Capital Corp.
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the...
Zenith Epigenetics Announces Clinical Trial Collaboration with Pfizer
20 nov. 2018 08h30 HE
|
Zenith Capital Corp.
Collaboration to evaluate ZEN-3694 in combination with Talazoparib in TNBC patients; Phase 1b/2 trial expected to initiate 1Q 2019 CALGARY, Alberta, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Zenith...